Comparative Pharmacology
Head-to-head clinical analysis: EMVERM versus STROMECTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMVERM versus STROMECTOL.
EMVERM vs STROMECTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Ivermectin acts by binding selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased permeability to chloride ions, hyperpolarization of nerve or muscle cells, and death of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA).
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
Oral: 200 mcg/kg once daily for 1-2 days. For strongyloidiasis, 200 mcg/kg/day for 2 days. For onchocerciasis, single dose of 150 mcg/kg.
None Documented
None Documented
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Terminal elimination half-life is approximately 18 hours (range 10–30 hours) in healthy subjects; prolonged in hepatic impairment.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Primarily fecal (90%) as unchanged drug and metabolites; renal excretion accounts for <1% of the dose.
Category C
Category C
Anthelmintic
Anthelmintic